Rubicon Research Expands Footprint with Arinna Lifesciences Acquisition

Rubicon Research has acquired a majority stake in Arinna Lifesciences for Rs 175.92 crores, aiming to boost its presence in the Indian CNS formulations market. This strategic move is expected to expand Rubicon's reach through Arinna's established sales network, while founder Vivek Seth retains a minority share.

Rubicon Research has announced the acquisition of a significant stake in Arinna Lifesciences, valued at Rs 175.92 crores. This move is part of Rubicon's strategic expansion into the Indian central nervous system (CNS) formulations market, leveraging its intellectual property and chronic product offerings.

The acquisition of an 85% equity shareholding is set to give Rubicon access to Arinna's extensive sales and distribution network in India, allowing them to reach both patients and prescribers. The company plans to capitalize on a pipeline of specialized products and drug-device combinations through this partnership.

Arinna's founder Vivek Seth will maintain a 15% ownership stake and continue as Managing Director. Rubicon's CEO, Parag Sancheti, highlighted the company's successful strategies in other markets and views Arinna as a key platform for similar growth in India.

(With inputs from agencies.)